ArticleJournal of the American Heart Association2018
Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS-BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment.
Article in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Predictive Performance of HAS-BLED Score in Patients with Atrial Fibrillation and Cancer: A Meta-Analysis.Cardiology · 2025Pooled it
- Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease.Journal of thrombosis and haemostasis : JTH · 2022Pooled it
- Impact of pharmacist-conducted anticoagulation patient education and telephone follow-up on transitions of care: a randomized controlled trial.BMC health services research · 2021Trial
- Performance of Bleeding Risk Scores for Major Bleeding in Anticoagulated Patients with Pulmonary Embolism: Insights from the CURES Registry-2.Thrombosis and haemostasis · 2026Article
- Risk-adapted venous thromboembolism prophylaxis in Asian patients admitted to medical intensive care unit: a prospective controlled trial.Thrombosis journal · 2025Article
- Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients.Cancer medicine · 2025Article
- Cardiovascular diseases in patients with cancer: A comprehensive review of epidemiological trends, cardiac complications, and prognostic implications.Chinese medical journal · 2025Review
- Finding individualised treatment in obese needing enoxaparin (FIT ONE): a multicentre study of therapeutic enoxaparin and the role of anti-factor Xa monitoring.Journal of thrombosis and thrombolysis · 2025Article
- Research progress on bleeding risk assessment models in anticoagulant therapy.Frontiers in cardiovascular medicine · 2025Review
- Using machine learning models to predict post-revascularization thrombosis in PAD.Frontiers in artificial intelligence · 2025Article
- Incidental deep venous thrombosis diagnosed on lower extremity computed tomography is a rare but clinically impactful finding.Journal of vascular surgery. Venous and lymphatic disorders · 2024Article
- Trajectories of adherence to extended treatment with direct oral anticoagulants and risks of recurrent venous thromboembolism and major bleeding.Journal of managed care & specialty pharmacy · 2023Article
- Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.Journal of thrombosis and thrombolysis · 2023Article
- Seeking a fine balance between effective antithrombotic prophylaxis and safety drug profile in the elderly population: the special case of traumatic brain injury.Acta neurochirurgica · 2023Article
- Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences.Advances in therapy · 2023Article
- Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice.Research and practice in thrombosis and haemostasis · 2023Article
- Mansoor's Self-Report Tool for Cardiovascular Risk Assessment predicts adverse in-hospital events in patients with pulmonary embolism.The clinical respiratory journal · 2023Article
- Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism.Clinical and translational science · 2023Article
- Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients-a prospective interventional study.Scientific reports · 2022Article
- Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR), Elderly, Drugs or alcohol use (HAS-BLED) score has strong predictive validity for major bleeding complications, but limited validation has been conducted in venous thromboembolism (VTE). This study evaluates the HAS-BLED score in a large cohort of VTE patients. METHODS AND
resultsA retrospective cohort of adults ≥18 years with primary diagnosis of VTE between January 1, 2010 and November 31, 2013 were identified in an insurance claims database. Patients were tracked until death, any bleed event, or end of study period. HAS-BLED score and components were evaluated via proportional hazard models. Cumulative incidence functions were reported at 30, 60, 90, and 180 days. N=132 280 patients with a VTE were identified, with 73.8% having HAS-BLED scores of 0 to 2, 3.6% score ≥4, and 4789 bleeding events (3.6% all patients). A 1-point HAS-BLED score increase was associated with 20% to 30% bleeding rate increase overall, but in a cancer cohort only the increase from 3- to 4-points was significant for all bleeds (csHR=1.41, 95% CI: 1.17-1.69; sdHR=1.40, 95% CI: 1.17-1.69) and major bleeds (csHR=1.66, 95% CI: 1.26-2.20; sdHR=1.66, 95% CI: 1.25-2.19). Adding cancer to the model as an independent covariate provided the strongest association among all covariates, with csHR=2.25 (95% CI: 1.98-2.56) and sdHR=2.11 (95% CI: 1.85-2.41) in the model for major bleeds.
conclusionsThe HAS-BLED score has good predictive validity for bleeding risks in patients with VTE. The addition of cancer as an independent bleeding risk factor merits consideration, possibly as part of the "B" criterion ("bleeding tendency or predisposition").
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.